Kodiak Sciences reported a third quarter 2026 net loss of US$66.22 million and a nine month loss of US$190.02 million while also highlighting positive Phase 3 data for retinal drug candidates Zenkuda ...
Source LinkKodiak Sciences reported a third quarter 2026 net loss of US$66.22 million and a nine month loss of US$190.02 million while also highlighting positive Phase 3 data for retinal drug candidates Zenkuda ...
Source Link
Comments